Article Text

Download PDFPDF

446 The administration of JAK and TYK2 inhibitor successfully ameliorated the severity of T cell transfer-induced colitis in mice
  1. Chunhui He1,
  2. Yanping Yuan2,
  3. Juan Wang2,
  4. Dongye Jia2,
  5. Xiangnan Qiang3,
  6. Ruiqing Yan1 and
  7. Nan Xie2
  1. 1WuXi AppTec, Nantong, Jiangsu Province, China
  2. 2WuXi AppTec, Shanghai, China
  3. 3WuXi AppTec, Cambridge, MA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s diseases, is recognized as an autoimmune disorder characterized by chronic inflammation of the digestive tract. Although the pathophysiology of IBD is not yet fully understood, genetic, gut microbial and environmental factors are believed to be involved. IBD remains a problematic disease as it can repeatedly relapse despite clinical therapy. To better understand the mechanisms of IBD, various animal models have been developed for research, including erosive and self-limiting models, spontaneous chronic colonic inflammation models induced by targeted gene deletion, and T cell-induced chronic colitis and intestinal inflammation model. Among all these models, T cell transfer IBD model is significantly more relevant to human disease than other models in terms of immunological mechanisms and regulation of chronic disease.

Methods Spleens from female Balb/c mice were harvested and ground into cell suspension. CD4-positive T cells were isolated from centrifuged cell suspension. Flow cytometry was used to select CD4+CD45RBhigh naive T cells for modelling and CD4+CD45RBlow naive T cells for negative control. Tofacitinib and BMS-986165 were selected as the positive control in the study. The Disease Activity Index (DAI) score which is the sum of body weight loss, stool consistency, and bleeding sub-scores, was used to assess the severity of colitis. After 42 days treatment, colons were harvested, and the excess tissue such as mesentery and adipose tissue was carefully removed. The length and weight of the colon were measured to calculate colon density.

Results The body weight of the mice in the Vehicle group decreased significantly compared with that in the CD4+CD45RBlow group. The DAI score of the mice in the Vehicle group significantly increased, confirming the successful establishment of the T cell transfer model. Both Tofacitinib and BMS-986165 treatment significantly increased the body weight and decreased the DAI score of the mice. The treatment also reduced the colon density compared to the CD4+CD45RBlow group.

Conclusions The T cell transfer IBD model was successfully established, presenting symptoms such as diarrhea, hematochezia, served body weight loss and increased colon density. Treatment with Tofacitinib and BMS-986165 ameliorated the severity of T cell transfer-induced colitis in mice. This was evidenced by reduced weight loss, improved stool consistency, and enhanced colon density through the JAK and TYK2 pathways.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.